New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (10.0% average weekly change). Valuation Update With 7 Day Price Move • Aug 13
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥81.32, the stock trades at a trailing P/E ratio of 68.1x. Average trailing P/E is 36x in the Pharmaceuticals industry in China. Total loss to shareholders of 18% over the past three years. Valuation Update With 7 Day Price Move • Jul 30
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥64.65, the stock trades at a trailing P/E ratio of 54.2x. Average trailing P/E is 33x in the Pharmaceuticals industry in China. Total loss to shareholders of 39% over the past three years. Announcement • Jun 30
Jenkem Technology Co., Ltd. to Report First Half, 2026 Results on Aug 26, 2026 Jenkem Technology Co., Ltd. announced that they will report first half, 2026 results on Aug 26, 2026 New Risk • Jun 03
New minor risk - Dividend sustainability The company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 0.4% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Valuation Update With 7 Day Price Move • May 18
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥83.85, the stock trades at a trailing P/E ratio of 70.2x. Average trailing P/E is 37x in the Pharmaceuticals industry in China. Total loss to shareholders of 29% over the past three years. New Risk • May 07
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 23% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 28% per year over the past 5 years. Minor Risk Large one-off items impacting financial results. Reported Earnings • Apr 29
Full year 2025 earnings released: EPS: CN¥1.02 (vs CN¥0.49 in FY 2024) Full year 2025 results: EPS: CN¥1.02 (up from CN¥0.49 in FY 2024). Revenue: CN¥318.2m (up 40% from FY 2024). Net income: CN¥61.7m (up 107% from FY 2024). Profit margin: 19% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings. Announcement • Apr 29
Jenkem Technology Co., Ltd., Annual General Meeting, May 25, 2026 Jenkem Technology Co., Ltd., Annual General Meeting, May 25, 2026, at 14:00 China Standard Time. Location: Tower C6, No. 66, Xixiaokou Road, Haidian District, Beijing China Announcement • Mar 30
Jenkem Technology Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026 Jenkem Technology Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026 Reported Earnings • Mar 05
Full year 2025 earnings released: EPS: CN¥1.05 (vs CN¥0.49 in FY 2024) Full year 2025 results: EPS: CN¥1.05 (up from CN¥0.49 in FY 2024). Revenue: CN¥316.1m (up 39% from FY 2024). Net income: CN¥63.4m (up 113% from FY 2024). Profit margin: 20% (up from 13% in FY 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings. New Risk • Feb 06
New major risk - Revenue and earnings growth Earnings have declined by 20% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 20% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). New Risk • Jan 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 26
Jenkem Technology Co., Ltd. to Report Fiscal Year 2025 Results on Apr 29, 2026 Jenkem Technology Co., Ltd. announced that they will report fiscal year 2025 results on Apr 29, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.31 (vs CN¥0.079 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.31 (up from CN¥0.079 in 3Q 2024). Revenue: CN¥81.0m (up 42% from 3Q 2024). Net income: CN¥18.7m (up 297% from 3Q 2024). Profit margin: 23% (up from 8.2% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 47 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Jenkem Technology Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Jenkem Technology Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jun 30
Jenkem Technology Co., Ltd. to Report First Half, 2025 Results on Aug 29, 2025 Jenkem Technology Co., Ltd. announced that they will report first half, 2025 results on Aug 29, 2025 Announcement • Apr 29
Jenkem Technology Co., Ltd., Annual General Meeting, Jun 10, 2025 Jenkem Technology Co., Ltd., Annual General Meeting, Jun 10, 2025, at 14:00 China Standard Time. New Risk • Apr 07
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (14% net profit margin). Announcement • Mar 28
Jenkem Technology Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Jenkem Technology Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 Reported Earnings • Mar 02
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: EPS: CN¥0.51 (down from CN¥1.92 in FY 2023). Revenue: CN¥223.5m (down 24% from FY 2023). Net income: CN¥30.8m (down 73% from FY 2023). Profit margin: 14% (down from 40% in FY 2023). The decrease in margin was primarily driven by lower revenue. Revenue missed analyst estimates by 25%. Earnings per share (EPS) exceeded analyst estimates by 47%. Revenue is forecast to grow 29% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 36% per year, which means it has not declined as severely as earnings. Valuation Update With 7 Day Price Move • Feb 25
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥63.00, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 72% over the past three years. New Risk • Jan 12
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Announcement • Dec 27
Jenkem Technology Co., Ltd. to Report Fiscal Year 2024 Results on Apr 29, 2025 Jenkem Technology Co., Ltd. announced that they will report fiscal year 2024 results on Apr 29, 2025 New Risk • Oct 31
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 21% Last year net profit margin: 37% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (11% average weekly change). Profit margins are more than 30% lower than last year (21% net profit margin). Reported Earnings • Oct 31
Third quarter 2024 earnings released: EPS: CN¥0.079 (vs CN¥0.54 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.079 (down from CN¥0.54 in 3Q 2023). Revenue: CN¥57.1m (down 22% from 3Q 2023). Net income: CN¥4.71m (down 85% from 3Q 2023). Profit margin: 8.2% (down from 44% in 3Q 2023). The decrease in margin was primarily driven by higher expenses. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has fallen by 42% per year, which means it is performing significantly worse than earnings. Valuation Update With 7 Day Price Move • Oct 15
Investor sentiment deteriorates as stock falls 25% After last week's 25% share price decline to CN¥56.52, the stock trades at a forward P/E ratio of 27x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total loss to shareholders of 77% over the past three years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.3% average weekly change). Announcement • Sep 30
Jenkem Technology Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024 Jenkem Technology Co., Ltd. announced that they will report Q3, 2024 results on Oct 31, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥53.66, the stock trades at a forward P/E ratio of 26x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total loss to shareholders of 79% over the past three years. Major Estimate Revision • Sep 07
Consensus EPS estimates fall by 23% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from CN¥345.5m to CN¥318.1m. EPS estimate also fell from CN¥2.30 per share to CN¥1.77 per share. Net income forecast to grow 67% next year vs 29% growth forecast for Pharmaceuticals industry in China. Consensus price target of CN¥94.00 unchanged from last update. Share price fell 6.5% to CN¥48.41 over the past week. Reported Earnings • Aug 30
Second quarter 2024 earnings released: EPS: CN¥0.22 (vs CN¥0.35 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.22 (down from CN¥0.35 in 2Q 2023). Revenue: CN¥63.8m (down 19% from 2Q 2023). Net income: CN¥13.5m (down 36% from 2Q 2023). Profit margin: 21% (down from 27% in 2Q 2023). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 38% per year, which means it is performing significantly worse than earnings. Announcement • Jun 28
Jenkem Technology Co., Ltd. to Report First Half, 2024 Results on Aug 30, 2024 Jenkem Technology Co., Ltd. announced that they will report first half, 2024 results on Aug 30, 2024 New Risk • Jun 05
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 31% Last year net profit margin: 45% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (8.7% average weekly change). Profit margins are more than 30% lower than last year (31% net profit margin). Reported Earnings • May 01
First quarter 2024 earnings released: EPS: CN¥0.24 (vs CN¥0.78 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.24 (down from CN¥0.78 in 1Q 2023). Revenue: CN¥64.8m (down 30% from 1Q 2023). Net income: CN¥14.5m (down 69% from 1Q 2023). Profit margin: 22% (down from 51% in 1Q 2023). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has fallen by 19% per year, which means it is performing significantly worse than earnings. Announcement • May 01
Jenkem Technology Co., Ltd., Annual General Meeting, May 24, 2024 Jenkem Technology Co., Ltd., Annual General Meeting, May 24, 2024, at 14:00 China Standard Time. Location: Block C6, No. 66, Xixiaokou Road, Haidian District, Beijing China Valuation Update With 7 Day Price Move • Apr 10
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to CN¥89.55, the stock trades at a forward P/E ratio of 34x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 11% over the past three years. New Risk • Apr 09
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (10% average weekly change). Announcement • Mar 29
Jenkem Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024 Jenkem Technology Co., Ltd. announced that they will report Q1, 2024 results on Apr 30, 2024 Reported Earnings • Feb 27
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: CN¥2.03 (down from CN¥3.11 in FY 2022). Revenue: CN¥299.1m (down 27% from FY 2022). Net income: CN¥122.7m (down 34% from FY 2022). Profit margin: 41% (down from 46% in FY 2022). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 26%. Revenue is forecast to grow 32% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Announcement • Feb 23
Jenkem Technology Co., Ltd. (SHSE:688356) announces an Equity Buyback for CNY 20 million worth of its shares. Sichuan Anning Iron and Titanium Co.,Ltd. (SZSE:002978) announces a share repurchase program. Under the program, the company will repurchase up to CNY 20 million worth of its shares. The shares will be repurchased at a price not more than CNY 125.22 per share. The repurchased share will be used for employee stock ownership plan and equity incentives. The funds for the repurchases are the company's own funds. The program will be valid for a period of 12 months. Valuation Update With 7 Day Price Move • Jan 31
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥72.03, the stock trades at a forward P/E ratio of 22x. Average forward P/E is 16x in the Pharmaceuticals industry in China. Total loss to shareholders of 22% over the past three years. Reported Earnings • Nov 02
Third quarter 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.89 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.54 (down from CN¥0.89 in 3Q 2022). Revenue: CN¥72.8m (down 31% from 3Q 2022). Net income: CN¥32.2m (down 40% from 3Q 2022). Profit margin: 44% (down from 51% in 3Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 28% After last week's 28% share price gain to CN¥119, the stock trades at a forward P/E ratio of 32x. Average forward P/E is 19x in the Pharmaceuticals industry in China. Total returns to shareholders of 33% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥115 per share. Reported Earnings • Aug 29
Second quarter 2023 earnings released: EPS: CN¥0.35 (vs CN¥0.99 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.35 (down from CN¥0.99 in 2Q 2022). Revenue: CN¥78.6m (down 31% from 2Q 2022). Net income: CN¥21.2m (down 64% from 2Q 2022). Profit margin: 27% (down from 52% in 2Q 2022). The decrease in margin was primarily driven by lower revenue. Revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Buying Opportunity • Aug 23
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 23%. The fair value is estimated to be CN¥115, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 36% over the last 3 years. Earnings per share has grown by 28%. Revenue is forecast to grow by 81% in 2 years. Earnings is forecast to grow by 90% in the next 2 years. Announcement • Jun 28
Jenkem Technology Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023 Jenkem Technology Co., Ltd. announced that they will report first half, 2023 results on Aug 29, 2023 Reported Earnings • May 03
First quarter 2023 earnings released: EPS: CN¥0.78 (vs CN¥0.87 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.78 (down from CN¥0.87 in 1Q 2022). Revenue: CN¥92.8m (down 8.0% from 1Q 2022). Net income: CN¥47.1m (down 10.0% from 1Q 2022). Profit margin: 51% (down from 52% in 1Q 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Buying Opportunity • Apr 03
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 11%. The fair value is estimated to be CN¥183, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 41% over the last 3 years. Earnings per share has grown by 32%. Revenue is forecast to grow by 108% in 2 years. Earnings is forecast to grow by 123% in the next 2 years. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: CN¥3.02 (vs CN¥2.93 in FY 2021) Full year 2022 results: EPS: CN¥3.02 (up from CN¥2.93 in FY 2021). Revenue: CN¥407.2m (up 16% from FY 2021). Net income: CN¥181.7m (up 3.4% from FY 2021). Profit margin: 45% (down from 50% in FY 2021). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Buying Opportunity • Nov 23
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 13%. The fair value is estimated to be CN¥232, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 45% over the last 3 years. Earnings per share has grown by 36%. Revenue is forecast to grow by 100% in 2 years. Earnings is forecast to grow by 96% in the next 2 years. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Nelson Li was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Oct 31
Third quarter 2022 earnings released: EPS: CN¥0.89 (vs CN¥1.03 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.89 (down from CN¥1.03 in 3Q 2021). Revenue: CN¥106.2m (flat on 3Q 2021). Net income: CN¥53.8m (down 13% from 3Q 2021). Profit margin: 51% (down from 58% in 3Q 2021). Revenue is forecast to grow 31% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 24% share price gain to CN¥185, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total loss to shareholders of 27% over the past year. Simply Wall St's valuation model estimates the intrinsic value at CN¥127 per share. Valuation Update With 7 Day Price Move • Sep 16
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥186, the stock trades at a forward P/E ratio of 40x. Average forward P/E is 18x in the Pharmaceuticals industry in China. Total loss to shareholders of 19% over the past year. Reported Earnings • Aug 26
Second quarter 2022 earnings released: EPS: CN¥0.99 (vs CN¥0.74 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.99 (up from CN¥0.74 in 2Q 2021). Revenue: CN¥113.9m (up 33% from 2Q 2021). Net income: CN¥59.1m (up 32% from 2Q 2021). Profit margin: 52% (in line with 2Q 2021). Valuation Update With 7 Day Price Move • Jun 20
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥228, the stock trades at a forward P/E ratio of 53x. Average forward P/E is 21x in the Pharmaceuticals industry in China. Total loss to shareholders of 7.3% over the past year. Valuation Update With 7 Day Price Move • Jun 02
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥198, the stock trades at a forward P/E ratio of 46x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total loss to shareholders of 7.7% over the past year. Reported Earnings • Apr 28
First quarter 2022 earnings released: EPS: CN¥0.87 (vs CN¥0.60 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.87 (up from CN¥0.60 in 1Q 2021). Revenue: CN¥100.8m (up 44% from 1Q 2021). Net income: CN¥52.3m (up 45% from 1Q 2021). Profit margin: 52% (in line with 1Q 2021). Reported Earnings • Mar 31
Full year 2021 earnings released: EPS: CN¥2.95 (vs CN¥1.71 in FY 2020) Full year 2021 results: EPS: CN¥2.95 (up from CN¥1.71 in FY 2020). Revenue: CN¥351.2m (up 88% from FY 2020). Net income: CN¥176.9m (up 107% from FY 2020). Profit margin: 50% (up from 46% in FY 2020). The increase in margin was driven by higher revenue. Reported Earnings • Feb 28
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: CN¥2.95 (up from CN¥1.71 in FY 2020). Revenue: CN¥351.2m (up 88% from FY 2020). Net income: CN¥176.9m (up 107% from FY 2020). Profit margin: 50% (up from 46% in FY 2020). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Jan 25
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥225, the stock trades at a trailing P/E ratio of 78.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in China. Total returns to shareholders of 129% over the past year. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥1.03 (vs CN¥0.57 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥106.1m (up 76% from 3Q 2020). Net income: CN¥61.7m (up 118% from 3Q 2020). Profit margin: 58% (up from 47% in 3Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • Aug 25
Second quarter 2021 earnings released: EPS CN¥0.74 (vs CN¥0.38 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥85.8m (up 123% from 2Q 2020). Net income: CN¥44.6m (up 165% from 2Q 2020). Profit margin: 52% (up from 44% in 2Q 2020). The increase in margin was driven by higher revenue. Reported Earnings • May 04
First quarter 2021 earnings released: EPS CN¥0.60 (vs CN¥0.24 in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥69.9m (up 159% from 1Q 2020). Net income: CN¥36.0m (up 230% from 1Q 2020). Profit margin: 52% (up from 40% in 1Q 2020). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥123, the stock trades at a trailing P/E ratio of 71.9x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥1.71 (vs CN¥1.37 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: CN¥186.6m (up 39% from FY 2019). Net income: CN¥85.7m (up 39% from FY 2019). Profit margin: 46% (in line with FY 2019). Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥104, the stock is trading at a trailing P/E ratio of 62.5x, up from the previous P/E ratio of 52.4x. This compares to an average P/E of 31x in the Pharmaceuticals industry in China. Is New 90 Day High Low • Feb 20
New 90-day low: CN¥86.68 The company is down 28% from its price of CN¥121 on 20 November 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Jan 13
New 90-day low: CN¥87.11 The company is down 18% from its price of CN¥106 on 15 October 2020. The Chinese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. Valuation Update With 7 Day Price Move • Jan 12
Investor sentiment deteriorated over the past week After last week's 18% share price decline to CN¥93.20, the stock is trading at a trailing P/E ratio of 56.2x, down from the previous P/E ratio of 68.5x. This compares to an average P/E of 32x in the Pharmaceuticals industry in China. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥110, the stock is trading at a trailing P/E ratio of 66.2x, up from the previous P/E ratio of 54.3x. This compares to an average P/E of 33x in the Pharmaceuticals industry in China. Is New 90 Day High Low • Dec 24
New 90-day low: CN¥90.16 The company is down 2.0% from its price of CN¥91.95 on 25 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is flat over the same period. Valuation Update With 7 Day Price Move • Nov 27
Market pulls back on stock over the past week After last week's 15% share price decline to CN¥103, the stock is trading at a trailing P/E ratio of 62x, down from the previous P/E ratio of 73x. This compares to an average P/E of 34x in the Pharmaceuticals industry in China. Announcement • Oct 29
Jenkem Technology Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020 Jenkem Technology Co., Ltd. announced that they will report Q3, 2020 results on Oct 30, 2020 Valuation Update With 7 Day Price Move • Oct 14
Market bids up stock over the past week After last week's 18% share price gain to CN¥107, the stock is trading at a trailing P/E ratio of 68.9x, up from the previous P/E ratio of 58.5x. This compares to an average P/E of 40x in the Chemicals industry in China. 
